Evidence map›Paper›PMID 30742097›Full record

ArticleOncogene2019

Downregulation of specific FBXW7 isoforms with differential effects in T-cell lymphoblastic lymphoma.

Irene Vázquez-Domínguez, Laura González-Sánchez, Pilar López-Nieva, Pablo Fernández-Navarro, María Villa-Morales, María Á Cobos-Fernández, Isabel Sastre, Mario F Fraga, Agustín F Fernández, Marcos Malumbres and 6 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Frontiers in oncology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Irene Vázquez-DomínguezCentro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
Laura González-SánchezCentro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
Pilar López-NievaCentro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
Pablo Fernández-NavarroUnidad de Epidemiología Ambiental y Cáncer, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain.
María Villa-MoralesCentro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.ORCID http://orcid.org/0000-0001-7906-0169
María Á Cobos-FernándezCentro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
Isabel SastreCentro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
Mario F FragaCentro de Investigación en Nanomateriales y Nanotecnología (CINN-CSIC), Universidad de Oviedo-Principado de Asturias, Oviedo, Spain.
Agustín F FernándezUnidad de Epigenética del Cáncer, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Fundación para la Investigación Biosanitaria de Asturias (FINBA), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-HUCA), Oviedo, Spain.ORCID http://orcid.org/0000-0002-3792-4085
Marcos MalumbresGrupo de División Celular y Cáncer, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
María Salazar-RoaGrupo de División Celular y Cáncer, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
Osvaldo Graña-CastroUnidad de Bioinformática, Biología Estructural y Biocomputación, Centro Nacional de Investigaciones Ocológicas (CNIO), Madrid, Spain.
Javier SantosCentro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
Pilar LlamasIIS Fundación Jiménez Díaz, Madrid, Spain.
José L López-LorenzoIIS Fundación Jiménez Díaz, Madrid, Spain.
José Fernández-PiquerasCentro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain. jfpiqueras@cbm.csic.es.ORCID http://orcid.org/0000-0003-4520-6785
Consejo Superior de Investigaciones Científicas · ESHospital Universitario Fundación Jiménez Díaz · ESSpanish National Cancer Research Centre · ESCentre for Biomedical Network Research on Rare Diseases · ESInstituto de Investigación Sanitaria del Principado de Asturias · ESInstituto de Salud Carlos III · ESUniversidad de Oviedo · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FBXW7 is a driver gene in T-cell lymphoblastic neoplasia acting through proteasome degradation of key proto-oncogenes. FBXW7 encodes three isoforms, α, β and γ, which differ only in the N-terminus. In this work, massive sequencing revealed significant downregulation of FBXW7 in a panel of primary T-cell lymphoblastic lymphomas characterised by the absence of mutations in its sequence. We observed that decreased expression mainly affected the FBXW7β isoform and to a lesser extent FBXW7α and may be attributed to the combined effect of epigenetic changes, alteration of upstream factors and upregulation of miRNAs. Transient transfections with miRNA mimics in selected cell lines resulted in a significant decrease of total FBXW7 expression and its different isoforms separately, with the consequent increment of critical substrates and the stimulation of cell proliferation. Transient inhibition of endogenous miRNAs in a T-cell lymphoblastic-derived cell line (SUP-T1) was capable of reversing these proliferative effects. Finally, we show how FBXW7 isoforms display different roles within the cell. Simultaneous downregulation of the α and γ isoforms modulates the amount of CCNE1, whilst the β-isoform alone was found to have a prominent role in modulating the amount of c-MYC. Our data also revealed that downregulation of all isoforms is a sine qua non condition to induce a proliferative pattern in our cell model system. Taking these data into account, potential new treatments to reverse downregulation of all or a specific FBXW7 isoform may be an effective strategy to counteract the proliferative capacity of these tumour cells.

Indexed as

Cell Line, TumorDown-RegulationEpigenesis, GeneticF-Box-WD Repeat-Containing Protein 7Gene Expression ProfilingGene Expression Regulation, EnzymologicGene Expression Regulation, LeukemicHumansIsoenzymesJurkat CellsMicroarray AnalysisMicroRNAsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaF-Box-WD Repeat-Containing Protein 7FBXW7 protein, humanIsoenzymesMicroRNAs

Identifiers

PMID30742097
OpenAlexW2915049808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.